ALDA Pharmaceuticals Corp.
TSX VENTURE : APH

ALDA Pharmaceuticals Corp.

June 25, 2008 14:10 ET

ALDA Pharmaceuticals Corp.: Revised Quarterly Reports to be Filed

VANCOUVER, BRITISH COLUMBIA--(Marketwire - June 25, 2008) - ALDA Pharmaceuticals Corp. (TSX VENTURE:APH) ("ALDA" or the "Company") has recently been through a vigorous review of its annual and interim financial disclosure and related management discussion and analysis as part of the British Columbia Securities Commission's ("BCSC") ongoing Continuous Disclosure Review Program. This program is intended to ensure that reporting issuers comply with applicable securities regulations and is meant to improve the quality of disclosure to shareholders and other market participants. The review focused on the Company's financial disclosure for the year ended June 30, 2007 and the subsequent quarterly periods ended September 30, 2007 and December 31, 2007.

The review identified several matters for which the Commission requested further detail and explanation with related Management Discussion and Analysis ("MD&A"), in accordance with Form 51-102F1 of National Instrument 51-102 - Continuous Disclosure Obligations, and the corresponding financials statements. Accordingly, ALDA is addressing these disclosure matters and will be submitting revised documents, to the extent necessary, to the BCSC shortly for review and confirmation. Thereafter the Company will re-file such amended and restated forms with SEDAR.

Dr. Terrance Owen, President & CEO, states, "All of ALDA's quarterly and annual filings have been filed with all the required regulatory bodies on time. The company is addressing the revised disclosure as required by the BCSC."

About ALDA Pharmaceuticals Corp.

ALDA is focused on the development of infection control therapeutics derived from its patent-pending T36® technology. The company trades on the TSX Venture Exchange under the symbol APH.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information

  • ALDA Pharmaceuticals Corp.
    Terrance G. Owen, Ph.D., MBA
    President, CEO and Director
    (604) 521-8300
    (604) 521-8322 (FAX)
    or
    ALDA Pharmaceuticals Corp.
    Peter Chen
    Distribution & Sales Contact
    (604) 521-8300 Ext. 3
    Email: peter_chen@aldacorp.com
    or
    ALDA Pharmaceuticals Corp.
    Scott Young
    Investor Relations Contact
    (604) 288-7222
    Email: syoung@freeformcom.com
    Website: www.aldacorp.com